Ozmosi | TRV120027 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

TRV120027

Alternative Names: trv120027
Clinical Status: Inactive
Latest Update: 2023-12-22
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: AT1 Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Trevena
Company Location: CHESTERBROOK PA 19087
Company CEO: Carrie L. Bourdow
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Heart Failure

Phase 1: Kidney Diseases|Heart Failure

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT01444872

 CP120027.1002

P1

Completed

Heart Failure|Kidney Diseases

2012-05-01

2019-03-19

Treatments

2010-020376-37

 2010-020376-37

P2

Completed

Heart Failure

2012-04-06

2025-07-05

Treatments

NCT01187836

 CP120027.2001

P2

Completed

Heart Failure

2012-03-01

2019-03-19

Treatments

Recent News Events

Date

Type

Title

12/22/2023

PubMed

 β-Arrestin pathway activation by selective ATR1 agonism promotes calcium influx in podocytes, leading to glomerular damage.

07/18/2023

PubMed

 The AT1/AT2 Receptor Equilibrium Is a Cornerstone of the Regulation of the Renin Angiotensin System beyond the Cardiovascular System.

07/15/2023

PubMed

 Gαq protein-biased ligand of angiotensin II type 1 receptor mediates myofibroblast differentiation through TGF-β1/ERK axis in human cardiac fibroblasts.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions